Efficacy of oral NAC and rectal indomethacin in prevention pancreatitis after ERCP

The comparison of efficacy of oral oral N-acetylcysteine (NAC) with rectal indomethacin in prevention of post ERCP pancreatitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201222049798N1

Enrollment

280

Registered

2020-12-29

Start date

2021-02-19

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis. Acute pancreatitis, unspecified

Interventions

Intervention 1: Intervention group: N-acetylcysteine 1200 mg (Osvah Pharmaceutical Company, Iran Exir CO., Iran) is drunk with 150 cc water two hours before endoscopic retrograde cholangiopancreatogra

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who candidate for endoscopic retrograde cholangiopancreatography (ERCP) including patients with jaundice due to biliary obstruction and imaging findings indicating pancreatic duct obstruction Consent to participate in the study

Exclusion criteria

Exclusion criteria: History of pancreatitis before ERCP Uncontrolled diabetes, Triglyceride more than 1000 mg/dL

Design outcomes

Primary

Measure	Time frame
Incidence of pancreatitis. Timepoint: 24 hours after ERCP. Method of measurement: Based on the amount of amylase increase (more than 276 IU/di) and the presence of abdominal pain and patient report of abdominal pain after ERCP.;Severity of pancreatitis. Timepoint: Duration of hospitalization. Method of measurement: Based on the number of hospitalization days (mild pancreatitis: hospitalization less than 4 days, moderate pancreatitis: 4 to 10 days; severe pancreatitis: more than 10 days).	—

Measure

Time frame

Incidence of pancreatitis. Timepoint: 24 hours after ERCP. Method of measurement: Based on the amount of amylase increase (more than 276 IU/di) and the presence of abdominal pain and patient report of abdominal pain after ERCP.;Severity of pancreatitis. Timepoint: Duration of hospitalization. Method of measurement: Based on the number of hospitalization days (mild pancreatitis: hospitalization less than 4 days, moderate pancreatitis: 4 to 10 days; severe pancreatitis: more than 10 days).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli akbar Abravesh

Ahvaz University of Medical Sciences

abravesh.aa@ajums.ac.ir+98 61 3222 2922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 10, 2026